These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 23290508)

  • 1. Pitfalls of drug development: lessons learned from trials of denufosol in cystic fibrosis.
    Moss RB
    J Pediatr; 2013 Apr; 162(4):676-80. PubMed ID: 23290508
    [No Abstract]   [Full Text] [Related]  

  • 2. Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function.
    Accurso FJ; Moss RB; Wilmott RW; Anbar RD; Schaberg AE; Durham TA; Ramsey BW;
    Am J Respir Crit Care Med; 2011 Mar; 183(5):627-34. PubMed ID: 21169471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis.
    Deterding RR; Lavange LM; Engels JM; Mathews DW; Coquillette SJ; Brody AS; Millard SP; Ramsey BW;
    Am J Respir Crit Care Med; 2007 Aug; 176(4):362-9. PubMed ID: 17446337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update in cystic fibrosis 2008.
    Ratjen F
    Am J Respir Crit Care Med; 2009 Mar; 179(6):445-8. PubMed ID: 19264980
    [No Abstract]   [Full Text] [Related]  

  • 5. Exciting new clinical trials in cystic fibrosis: infants need not apply.
    Stick SM; Sly PD
    Am J Respir Crit Care Med; 2011 Jun; 183(12):1577-8. PubMed ID: 21693709
    [No Abstract]   [Full Text] [Related]  

  • 6. Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis.
    Deterding R; Retsch-Bogart G; Milgram L; Gibson R; Daines C; Zeitlin PL; Milla C; Marshall B; Lavange L; Engels J; Mathews D; Gorden J; Schaberg A; Williams J; Ramsey B;
    Pediatr Pulmonol; 2005 Apr; 39(4):339-48. PubMed ID: 15704203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug developers aim to treat cystic fibrosis through disease modification.
    Thompson CA
    Am J Health Syst Pharm; 2008 Dec; 65(24):2310-2. PubMed ID: 19052266
    [No Abstract]   [Full Text] [Related]  

  • 8. Novel agents in cystic fibrosis.
    Storey S; Wald G
    Nat Rev Drug Discov; 2008 Jul; 7(7):555-6. PubMed ID: 18591977
    [No Abstract]   [Full Text] [Related]  

  • 9. Long term effects of denufosol tetrasodium in patients with cystic fibrosis.
    Ratjen F; Durham T; Navratil T; Schaberg A; Accurso FJ; Wainwright C; Barnes M; Moss RB;
    J Cyst Fibros; 2012 Dec; 11(6):539-49. PubMed ID: 22682898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Denufosol: a review of studies with inhaled P2Y(2) agonists that led to Phase 3.
    Kellerman D; Rossi Mospan A; Engels J; Schaberg A; Gorden J; Smiley L
    Pulm Pharmacol Ther; 2008 Aug; 21(4):600-7. PubMed ID: 18276176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hitting the target: new treatments for cystic fibrosis.
    Davis SD; Ferkol TW
    Am J Respir Crit Care Med; 2010 Dec; 182(12):1460-1. PubMed ID: 21159902
    [No Abstract]   [Full Text] [Related]  

  • 12. Resource use, costs, and utility estimates for patients with cystic fibrosis with mild impairment in lung function: analysis of data collected alongside a 48-week multicenter clinical trial.
    Dewitt EM; Grussemeyer CA; Friedman JY; Dinan MA; Lin L; Schulman KA; Reed SD
    Value Health; 2012; 15(2):277-83. PubMed ID: 22433759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cystic fibrosis lung disease starts in the small airways: can we treat it more effectively?
    Tiddens HA; Donaldson SH; Rosenfeld M; Paré PD
    Pediatr Pulmonol; 2010 Feb; 45(2):107-17. PubMed ID: 20082341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experience using centralized spirometry in the phase 2 randomized, placebo-controlled, double-blind trial of denufosol in patients with mild to moderate cystic fibrosis.
    Goss CH; McKone EF; Mathews D; Kerr D; Wanger JS; Millard SP;
    J Cyst Fibros; 2008 Mar; 7(2):147-53. PubMed ID: 17728193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging therapies for cystic fibrosis lung disease.
    Grasemann H; Ratjen F
    Expert Opin Emerg Drugs; 2010 Dec; 15(4):653-9. PubMed ID: 20812885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biotechnology. Disease group invests in do-it-yourself drugs.
    Marshall E
    Science; 2000 Jun; 288(5472):1715-7. PubMed ID: 10877679
    [No Abstract]   [Full Text] [Related]  

  • 17. Relationships between cystic fibrosis transmembrane conductance regulator, extracellular nucleotides and cystic fibrosis.
    Marcet B; Boeynaems JM
    Pharmacol Ther; 2006 Dec; 112(3):719-32. PubMed ID: 16828872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhaled P2Y2 receptor agonists as a treatment for patients with Cystic Fibrosis lung disease.
    Kellerman D; Evans R; Mathews D; Shaffer C
    Adv Drug Deliv Rev; 2002 Dec; 54(11):1463-74. PubMed ID: 12458155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging therapies in cystic fibrosis.
    Anderson P
    Ther Adv Respir Dis; 2010 Jun; 4(3):177-85. PubMed ID: 20530065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel de novo large deletion in cystic fibrosis transmembrane conductance regulator gene results in a severe cystic fibrosis phenotype.
    Norek A; Stremska M; Sobczyńska-Tomaszewska A; Wertheim-Tysarowska K; Dmeńska H; Jurek M
    J Pediatr; 2011 Aug; 159(2):343-6.e1. PubMed ID: 21663921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.